Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase–primase inhibitor pritelivir

Andrei, 2005, J. Virol., 79, 5863, 10.1128/JVI.79.9.5863-5869.2005 Andrei, 2007, DNA polymerase mutations in drug-resistance herpes simplex virus mutants determine in vivo neurovirulence and drug–enzyme interactions, Antiviral Therapy, 12, 719, 10.1177/135965350701200502 Andrei, 2013, Heterogeneity and evolution of thymidine kinase and DNA polymerase mutants of herpes simplex virus type 1: implications for antiviral therapy, J. Infect. Dis., 207, 1295, 10.1093/infdis/jit019 Bacon, 2003, Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy, Clin. Microb. Rev., 16, 114, 10.1128/CMR.16.1.114-128.2003 Biswas, 2011, Helicase–primase inhibitors: a new approach to combat herpes simplex virus and varicella zoster virus, 129 Biswas, 2007, Detection of HSV-1 variants highly resistant to the helicase–primase inhibitor BAY 57-1293 at high frequency in two of ten recent clinical isolates of HSV-1, J. Antimicrob. Chemother., 60, 274, 10.1093/jac/dkm182 Field, 2011, Antiviral drug resistance and helicase–primase inhibitors of herpes simplex virus, Drug Resist. Updates, 14, 45, 10.1016/j.drup.2010.11.002 Field, 2013, The helicase–primase complex as a target for effective herpesvirus antivirals, 145 http://www.aicuris.com/10d72/News_Publications.htm. Last accessed 24 April, 2013. Huang, M.L., Diem, K., Selke, S., Wald, A., Corey, L., Zimmermann, H., Ruebsamen-Schaeff, H., Birkmann, A. 2011. No emergence of resistance under treatment with the novel HSV inhibitor AIC316 in persons with genital herpes. In: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, USA. Kleymann, 2002, New helicase–primase inhibitors as drug candidates for the treatment of herpes simplex disease, Nat. Med., 8, 392, 10.1038/nm0402-392